Market Overview

Tay-Sachs Disease Prevalence Forecast In 19 Major Markets 2018-2028


Dublin, Aug. 10, 2018 (GLOBE NEWSWIRE) -- The "Tay-Sachs Disease Forecast In 19 Major Markets 2018-2028" report has been added to's offering.

Hexosaminidase A deficiency (HEX A deficiency) results in a group of neurodegenerative disorders caused by the dysfunctional activity of the specific glycosphingolipid GM2 ganglioside. The disease occurs when cell membrane components known as gangliosides, accumulate to toxic levels, particularly in neurons in the brain and spinal cord, leading to the destruction of neurons and interference with biological functions. The predominant HEX A deficiency is Tay-Sachs disease (TSD) with its common acute infantile variant, which begins around six months of age and usually results in death by the age of four. Alternative variants of the pathology are the juvenile and the adult-onset TSD types.

This report provides the current prevalent population for TSD disease across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Czech Republic, Portugal, Russia, Turkey, Saudi Arabia, Japan, China, India, Australia, Brazil) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, patients with main phenotypes and multiple symptoms of TSD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for TSD include:

  • Visual problems
  • Low muscle tone
  • Seizures
  • Neuromuscular abnormalities
  • Speech disturbances
  • Cerebellar dysfunctions/Impaired cognitive status

Reasons to buy

  • Able to quantify patient populations in global TSD market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of TSD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on TSD prevalent population.
  • Identify sub-populations within TSD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of TSD patients.

Key Topics Covered:

  1. List Of Tables And Figures
  2. Introduction
  3. Cause Of The Disease
  4. Risk Factors & Prevention
  5. Diagnosis Of The Disease
  6. Variation By Geography/Ethnicity
  7. Disease Prognosis & Clinical Course
  8. Key Comorbid Conditions / Features Associated With The Disease
  9. Methodology For Quantification Of Patient Numbers
  10. Top-Line Prevalence For Tay-Sachs Disease
  11. Features Of Tay-Sachs Disease Patients
  12. Infantile Phenotype
  13. Juvenile Phenotype
  14. Adult (Lots) Phenotype
  15. Abbreviations Used In The Report
  16. Other Services & Solutions
  17. Reports & Publications
  18. Online Epidemiology Databases
  19. Online Pharmaceutical Pricing Database
  20. References
  21. Appendix

For more information about this report visit

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs 

Primary Logo

View Comments and Join the Discussion!

Latest Ratings

MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.